Neurogene doses multiple participants in Embolden Rett trial; interim data mid-2026

Neurogene Inc.

Dosed multiple participants in Embolden registrational trial in Q4 2025; expect to complete dosing Q2 2026.
Plan to present interim Phase 1/2 data (8 pediatric, 2 adolescent/adult) with >=12-month follow-up mid-2026.
Cash runway through Q1 2028; early commercial-readiness activities underway including payor research.
Initiated 13 U.S. clinical trial sites; presenting at J.P. Morgan Healthcare Conference on Jan 14, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.